Mesoblast (MESO) Net Cash Flow (QoQ) (2016 - 2023)
Powered by 
Analysis
Mesoblast (MESO) Net Cash Flow (QoQ) (2016 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Mesoblast | 2.24 Bn | 2.14 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 285.72% |
| Mar 31, 2023 | -656.95% |
| Dec 31, 2022 | -73.51% |
| Sep 30, 2022 | 436.58% |
| Jun 30, 2022 | 10.72% |
| Mar 31, 2022 | 14.56% |
| Dec 31, 2021 | -232.80% |
| Sep 30, 2021 | 174.60% |
| Jun 30, 2021 | -126.41% |
| Mar 31, 2021 | 355.13% |
| Dec 31, 2020 | -46.19% |
| Mar 31, 2020 | -67.51% |
| Dec 31, 2019 | 293.06% |
| Mar 31, 2019 | -112.11% |
| Dec 31, 2018 | 215.44% |
| Sep 30, 2018 | 180.99% |
| Jun 30, 2018 | -279.46% |
| Mar 31, 2018 | 178.10% |
| Dec 31, 2017 | -188.39% |
| Sep 30, 2017 | 174.88% |